US Continuous Glucose Monitoring Market Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 6.21 Billion |
| Market Size (2030) | USD 10.76 Billion |
| CAGR (2025 - 2030) | 11.64% |
| Market Concentration | High |
Major Players*Disclaimer: Major Players sorted in no particular order |
US Continuous Glucose Monitoring Market Analysis
The US Continuous Glucose Monitoring Market size is estimated at USD 6.21 billion in 2025, and is expected to reach USD 10.76 billion by 2030, at a CAGR of 11.64% during the forecast period (2025-2030).
Regularly monitoring blood glucose levels is pivotal for managing diabetes effectively and mitigating associated health risks. Elevated blood glucose levels in diabetic patients can lead to complications, including kidney, nerve, and eye damage. Monitoring helps evaluate glucose metabolism efficiency, aiding in achieving optimal glycemic control. Over time, this data assists in tailoring precise diabetes management plans for patients and healthcare providers.
According to a September 2023 report by the National Centre for Health Statistics, 41.9% of United States adults struggle with obesity, with rural areas showing higher rates than urban and suburban regions. Obesity prompts fat cells to release pro-inflammatory chemicals, diminishing the body's insulin sensitivity. Consequently, obese individuals might require insulin injections and continuous glucose monitoring for effective management.
Moreover, the advent of such monitoring devices is poised to propel market growth. For instance, in March 2024, the FDA approved one of the first over-the-counter CGMs by Dexcom, which is tailored for type 2 diabetes patients, underlining its heightened efficacy and cost-effectiveness compared to traditional methods.
Advancements in CGM technology allow for both real-time monitoring and retrospective data analysis. Innovations such as the Minimed 780 and Guardian 4 CGM sensors have addressed prior technical hurdles. Meanwhile, upcoming models like the Eversense E3 CGM promise extended sensor lifespans and reduced calibration needs, further brightening the market's future prospects.
With rising rates of diabetes and obesity, alongside these technological advancements, the market is poised for substantial growth.
US Continuous Glucose Monitoring Market Trends
Rising Diabetes Prevalence in the United States
Over the past two decades, the United States has witnessed a significant surge in diabetes cases owing to the rising rates of obesity. his trend is further fueled by changing lifestyles, marked by decreased physical activity and the adoption of unhealthy dietary habits.
The 2023 update of the CDC National Diabetes Statistics Report revealed that over 136 million United States adults are living with diabetes or prediabetes. Type 2 diabetes prevails, with communities of color, rural residents, and individuals with lower education, income, and health literacy facing heightened risks.
Various organizations are issuing guidelines to promote continuous monitoring of glucose levels. For instance, in December 2023, the American Diabetes Association released its 2024 Standards of Care in Diabetes. These standards underscore the importance of early continuous glucose monitoring (CGM) for type 1 diabetes, even at diagnosis. They also stress the need to assist students in adopting diabetes technologies, such as CGM and insulin delivery systems, as advised by healthcare providers.
The 2022 World Health Assembly Resolution emphasizes integrating diabetes prevention and treatment into primary health services. It calls for expanded insulin access, streamlined regulatory requirements for diabetes medications and technologies, and enhanced monitoring and surveillance. Additionally, it tasks the WHO with ensuring continuous diabetes care during humanitarian crises, setting a global agenda for diabetes management in the coming decade.
Hence, the market under study is expected to surge during the forecast period, driven by increasing prevalence and the factors mentioned earlier.
The sensors segment is expected to witness the Significant growth rate over the forecast period
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase, in turn, converts glucose to hydrogen peroxide. This hydrogen peroxide then interacts with the platinum within the sensor, generating an electrical signal that is subsequently relayed to the transmitter.
Sensors stand out as the cornerstone of continuous glucose monitoring. Anticipated technological enhancements aimed at bolstering sensor accuracy are poised to propel segment growth through the forecast period.
Researchers are actively exploring alternatives to electrochemical-based glucose sensors, striving to develop CGM sensors that are more cost-effective, less invasive, and more user-friendly. Optical measurement emerges as a promising avenue for glucose sensing.
Advanced technologies such as spectroscopy, fluorescence, and holography are making waves in continuous glucose monitoring. For instance, Eversense, a CGM sensor from Senseonics, uses fluorescence sensing. It stands out for its significantly longer lifespan compared to traditional electrochemical sensors. Similarly, in April 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care reported the FDA's approval of Eversense as an integrated CGM (iCGM) device.
As highlighted by the Centre for Health Care Strategies, Medicaid agencies that expand coverage for CGMs can not only benefit their beneficiaries but also bolster the broader healthcare system. There's compelling evidence supporting the advantages of CGM usage for individuals reliant on insulin, whether through pumps or multiple daily injections. Furthermore, emerging data indicates the growing benefits of CGMs even for patients on basal insulin. The aforementioned factors are set to boost market growth.
US Continuous Glucose Monitoring Industry Overview
The United States continuous glucose monitoring market is consolidated, with a few significant players. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, have sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring market. There have been constant innovations driven by manufacturers such as Abbott and Medtronic while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
US Continuous Glucose Monitoring Market Leaders
-
Abbott Diabetes Care
-
Dexcom Inc.
-
Ascensia Diabetes Care
-
Medtronic
-
GlySens
- *Disclaimer: Major Players sorted in no particular order
US Continuous Glucose Monitoring Market News
- June 2024: Abbott received the United States FDA's 510(k) clearance for its over-the-counter Lingo glucose-monitoring biowearable.
- February 2024: Ultrahuman introduced its continuous glucose monitor, the Ultrahuman M1 CGM, in the United States. This compact device attaches to the back of the arm and continuously measures glucose levels for a duration of 14 days.
US Continuous Glucose Monitoring Industry Segmentation
Achieving optimal glycemic results can be very difficult without frequent monitoring of blood glucose levels. A continuous glucose monitor tracks blood sugar levels 24 hours a day. It collects readings automatically every five to 15 minutes and detects trends and patterns to provide a complete picture of diabetes. The United States continuous glucose monitoring market is segmented by components and end users. By components, the market is segmented into sensors and durables. The durables include receivers and transmitters. By end user, the market is segmented into hospitals/clinics and home/personal. The report offers the value (USD) for the above segments.
| By Component | Sensors |
| Durables (Receivers and Transmitter) | |
| By End User | Hospitals/Clinics |
| Home/Personal |
US Continuous Glucose Monitoring Market Research FAQs
How big is the US Continuous Glucose Monitoring Market?
The US Continuous Glucose Monitoring Market size is expected to reach USD 6.21 billion in 2025 and grow at a CAGR of 11.64% to reach USD 10.76 billion by 2030.
What is the current US Continuous Glucose Monitoring Market size?
In 2025, the US Continuous Glucose Monitoring Market size is expected to reach USD 6.21 billion.
Who are the key players in US Continuous Glucose Monitoring Market?
Abbott Diabetes Care, Dexcom Inc., Ascensia Diabetes Care, Medtronic and GlySens are the major companies operating in the US Continuous Glucose Monitoring Market.
What years does this US Continuous Glucose Monitoring Market cover, and what was the market size in 2024?
In 2024, the US Continuous Glucose Monitoring Market size was estimated at USD 5.49 billion. The report covers the US Continuous Glucose Monitoring Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the US Continuous Glucose Monitoring Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
US Continuous Glucose Monitoring Industry Report
Statistics for the 2025 US Continuous Glucose Monitoring market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Continuous Glucose Monitoring analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
